Answers are grounded in this paper and cite their sources.
Importance Opioid overdose is a leading cause of preventable death in the US, yet there is widespread underuse of medications for opioid use disorder (MOUD), including buprenorphine, methadone, and extended-release naltrexone. Surgical care is a frequent health care encounter where continuity of MOUD use can influence perioperative safety and long-term outcomes. National data assessing trends in preoperative MOUD use are unavailable among Medicaid patients, who account for a disproportionate share of patients with opioid use disorder. Objective To assess national trends in the prevalence of preoperative MOUD use among Medicaid patients undergoing surgery, overall and across subgroups by MOUD type, demographics, and surgical procedure categories. Design, Setting, and Participants This retrospective cohort study used data from the Transformed Medicaid Statistical Information System Analytic Files for surgical procedures performed between July 1, 2016, and December 31, 2021. Patients aged 12 to 64 years with continuous Medicaid enrollment for 180 days before surgery were included. Data were analyzed from December 11, 2024, to June 29, 2025. Main Outcomes and Measures The primary outcome was preoperative MOUD use, defined as any claim for buprenorphine, methadone, or naltrexone use within 180 days before surgery. Unadjusted and adjusted annual prevalence estimates were calculated using logistic regression models with demographic and clinical covariates. Secondary outcomes included prevalence by medication type and by surgical procedure category. Results The study cohort included 7 967 328 Medicaid beneficiaries undergoing 13 115 728 procedures during the study period (mean [SD] age, 40.7 [15.0] years; 8 551 437 [65.2%] female, 4 564 291 [34.8%] male). The overall prevalence of preoperative MOUD use increased from 1440.0 to 2278.3 per 100 000 procedures; after adjusting for demographic, insurance, and clinical factors, the prevalence increased from 185.8 to 337.1 per 100 000 procedures. Buprenorphine use accounted for most of the increase, rising from 808.8 to 1453.5 per 100 000 procedures, while smaller gains were observed for methadone use (589.6 to 756.5 per 100 000 procedures) and naltrexone use (69.9 to 129.2 per 100 000 procedures). Prevalence was highest among tricuspid or mitral valve repair procedures (11 393.8 per 100 000 procedures). Sensitivity analyses excluding states and years with lower data quality yielded similar results. Conclusions and Relevance This cohort study found that among Medicaid beneficiaries undergoing surgery, preoperative MOUD use increased substantially during the study period, with growth across all major medication types. These findings highlight the need for evidence-based strategies to optimize the perioperative care of patients using MOUD.
No takes yet. Share an insight, caveat, or question.
Bicket et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: